Philadelphia Scientists Win $3 Million Breakthrough Prize for First FDA-Approved Gene Therapy for Inherited Blindness
Key Insights
Three Philadelphia scientists received the 2026 Breakthrough Prize for developing Luxturna, the first FDA-approved gene therapy for inherited genetic disease, specifically targeting Leber congenital amaurosis (search) caused by RPE65 (search) gene mutations.
The therapy delivers a functional copy of the RPE65 (search) gene directly into patients' eyes using a viral vector, improving vision in 72% of trial participants who showed maximum improvement in low-light conditions.
Their groundbreaking work established the scientific and regulatory framework for gene therapy development, paving the way for more than 140 retinal gene therapy trials and over a dozen similar FDA approvals.
Three Philadelphia scientists have been awarded the prestigious $3 million Breakthrough Prize for developing the first FDA-approved gene therapy for an inherited genetic disease. Jean Bennett and Albert Maguire, emeritus professors at the University of Pennsylvania, and Katherine High, CEO of RhyGaze (search) and emeritus professor at Children's Hospital of Philadelphia, received the honor at the "Oscars of Science" ceremony in Los Angeles for their groundbreaking work on Luxturna.
Their therapy, approved by the FDA in 2017, treats inherited retinal diseases (search) caused by mutations in the RPE65 (search) gene, notably Leber congenital amaurosis (search). This genetic condition causes severe vision loss or blindness over time as retinal cells degenerate and die. By delivering a functional copy of the affected gene directly to patients' eyes, the scientists demonstrated they could improve vision and slow disease progression.
From Laboratory Discovery to Clinical Breakthrough
The collaboration began in the early 1990s when Bennett and Maguire, who met as medical students at Harvard, started developing the technical aspects of their gene therapy approach. Their breakthrough came in July 2000 when they tested their therapy on dogs with the same genetic mutation affecting humans.
"Within a week, they received a call from their collaborators. The dogs were running around without bumping into things, which they couldn't do beforehand," Bennett recalled. The treated dogs were even stealing kibble from other dogs who couldn't see the food bowl as well. "It was really a eureka moment," she said.
The therapy uses a "gutted" virus as a vector to carry a functional copy of the mutated RPE65 (search) gene. Using a needle the diameter of three strands of hair, the treatment is injected directly into the eye. This approach targets diseases where children can generally see only incredibly bright light at birth, with their limited vision disappearing over time as cells degenerate.
Clinical Trial Success and Regulatory Approval
High's expertise in advancing research discoveries through clinical trials proved crucial when the gene therapy field faced setbacks following Jesse Gelsinger's death in 1999, the first fatality from a gene therapy clinical trial. Despite investor reluctance, High established vector production capabilities at CHOP and approached Bennett about moving their "great dog results" into humans.
By 2007, the team launched their clinical trial, initially with three adult patients. Early safety data persuaded regulators to include children, marking the first time children without a fatal disease participated in gene therapy trials. The researchers developed a mobility test to measure "functional vision" in daily living, consisting of a course with guiding arrows and obstacles like steps and doors.
In their pivotal phase 3 trial, 72% of the 37 eligible participants reported the maximum possible improvement in low-light conditions simulating night vision. Many also experienced improved peripheral and central vision. One patient who could only detect changes in light was suddenly able to navigate Philadelphia at night unaided and could make out the clock on City Hall. Another patient saw a star for the first time just six days after the procedure.
Establishing a New Therapeutic Paradigm
Luxturna works for patients with RPE65 (search) gene mutations, which account for approximately 5% to 10% of Leber congenital amaurosis (search) cases. The therapy was initially priced at $425,000 per eye and is now owned by Swiss pharmaceutical giant Roche following their 2019 acquisition of Spark Therapeutics (search). Most of the roughly 1,000 people estimated to be eligible in the U.S. have been treated, with the therapy expanding into overseas markets.
While commercially modest with 2025 sales of about $50 million, Luxturna's scientific impact has been transformative. According to High, about 15 gene therapy products now have FDA approval to treat genetic diseases. The success has inspired more than 140 gene therapy trials for retinal conditions, including macular degeneration (search) and diabetic retinopathy (search), with 80 trials currently underway.
Legacy and Future Impact
"Their discovery not only has advanced treatment for retinal disorders, but also charts the path for new gene therapies," said Huda Zoghbi, chair of the selection committee for the Breakthrough Prize in Life Sciences. The work has established Philadelphia as a biotech hub and bolstered the reputation of companies like Spark Therapeutics (search) as pioneering gene therapy developers.
The recognition marks the ninth Breakthrough Prize for Penn-affiliated researchers, tying with Harvard University for the most awards. Previous Penn Medicine winners include Carl June for CAR-T cell therapy, Drew Weissman and Katalin Karikó for mRNA technology, and Virginia Lee for Alzheimer's research.
Bennett described feeling "thrilled and honored, and humbled" to share the prize, recalling how patients and families described the therapy changing their lives during FDA approval meetings. "It still makes me well up with tears thinking about some of the stories people told," she said. The therapy represents a landmark achievement that has opened new possibilities for treating genetic diseases through targeted gene delivery.